---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-023646"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-07-28T23:59:59+00:00"
generated_at: "2026-05-18T00:07:00.049492+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports neflamapimod 54% risk reduction on CDR-SB at Week 32 in DLB trial

## Summary
- At Week 32, neflamapimod showed 54% risk reduction in >=1.5-point CDR-SB worsening vs control (p=0.0037); 64% in ptau181<2.2 patients (p=0.0001).
- Significant reduction in plasma GFAP biomarker: mean change -18.4 pg/mL (p<0.0001) for New Capsules over 32 weeks.
- Plans to initiate Phase 3 trial and meet with FDA in Q4 2025 to align on trial design.
- New Capsules achieved target plasma exposures; Old Capsules did not; similar safety profiles.
- Trial funded by $21.3M NIH/NIA grant; 43 sites across US, UK, Netherlands.

## SEC filing metadata
- accession: 0001437749-25-023646
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-07-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925023646/0001437749-25-023646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925023646/crvo20250728_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-023646
- JSON: https://secwatch.observer/filing/0001437749-25-023646.json
- Plain text: https://secwatch.observer/filing/0001437749-25-023646.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.